99 related articles for article (PubMed ID: 31223029)
21. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
22. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
23. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
24. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
25. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
26. Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.
Luo H; Zhong Q; Chen LJ; Qi XR; Fu AF; Yang HS; Yang F; Lin HG; Wei YQ; Zhao X
J Cancer Res Clin Oncol; 2008 Sep; 134(9):937-45. PubMed ID: 18350317
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
28. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
Chen J; Adikari M; Pallai R; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2008 May; 61(6):979-87. PubMed ID: 17661040
[TBL] [Abstract][Full Text] [Related]
29. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
Zhang N; Dai L; Qi Y; Di W; Xia P
Int J Oncol; 2013 Jun; 42(6):2053-9. PubMed ID: 23592281
[TBL] [Abstract][Full Text] [Related]
30. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
31. Raman micro-spectroscopy applied to treatment resistant and sensitive human ovarian cancer cells.
Moradi H; Ahmad A; Shepherdson D; Vuong NH; Niedbala G; Eapen L; Vanderhyden B; Nyiri B; Murugkar S
J Biophotonics; 2017 Oct; 10(10):1327-1334. PubMed ID: 28009133
[TBL] [Abstract][Full Text] [Related]
32. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
35. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
36. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
37. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling.
Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P
Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467
[TBL] [Abstract][Full Text] [Related]
38. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
39. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to cisplatin.
Raaphorst GP; Mao J; Yang H; Goel R; Niknafs B; Shirazi FH; Yazdi HM; Rippstein P; Ng CE
Anticancer Res; 1998; 18(4C):2945-51. PubMed ID: 9713489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
